Standard treatments for pancreatic cancer are often ineffective as they cannot be directly delivered to the tumor.
A potential new option for targeted treatment is on the horizon.
Pancreatic cancer is one of the deadliest types of cancer. Despite several FDA-approved treatments, it is projected to become the second-leading cause of cancer-related death in the United States around 2020[i], in part due to challenges in diagnosing and treating the disease. It is hard to detect at an early stage, usually not treatable by surgery, and resistant to drugs that work in many other cancers.[ii] A potential new option for targeted treatment is on the horizon.
[i] Lola Rahib et al. “Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States.” Cancer Research. Published Online First May 19, 2014.
[ii] Jim Stallard. Why is Pancreatic Cancer so Hard to Treat, Memorial Sloane Kettering Cancer Center, accessed March 20, 2019.
RenovoRx’s TIGeR-PaC pivotal study is currently enrolling newly-diagnosed locally advanced pancreatic cancer patients. This is a randomized study of Trans-Arterial Micro-Perfusion (TAMP™) vs. systemic chemotherapy.
70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is reporting her levels to be down and she is feeling great and that she believes this new procedure should be available to everyone.
Based on results of early studies highlighted by this patient’s and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial to further test this promising new procedure for pancreatic cancer patients.
